(Industry, academic, and healthcare partners gather at the official opening ceremony of the CREATIVE LIFE SCIENCE Zhubei Biomedical Factory, marking a new milestone in the company’s regenerative medicine manufacturing journey.)
Chi-Sen Biotech Officially Opens Asia’s First Regenerative Medicine PIC/S GMP Cell Culture Medium Manufacturing Base
CREATIVE LIFE SCIENCE (Stock Code: 7837) today announced the official opening of the CREATIVE LIFE SCIENCE Zhubei Biomedical Factory, a new PIC/S GMP-designed facility located within the Zhubei Biomedical Science Park. The new site represents a significant milestone in the company’s long-term strategy to build an internationally aligned regenerative medicine manufacturing and quality platform.
Designed to support the evolving needs of the global biotechnology and regenerative medicine industries, the Zhubei facility strengthens CREATIVE LIFE SCIENCE’s ability to provide scalable, compliant, and high-quality manufacturing support for advanced healthcare products and partners worldwide.
Chairman Yueh-Hung Tsai stated that the Zhubei Biomedical Factory reflects the company’s long-term commitment to becoming a trusted manufacturing and quality partner for the regenerative medicine era.
“As regenerative medicine continues to evolve globally, our goal is not only to build manufacturing capacity, but to create a platform that helps our partners accelerate development with greater confidence, quality assurance, and international compliance,” said Tsai.
“The Zhubei Biomedical Factory was established to support customers seeking stable, globally aligned manufacturing solutions for the next generation of healthcare products.”
Founded over 46 years ago, CREATIVE LIFE SCIENCE has built its reputation through microbiology-related products, testing services, and quality management expertise. Today, the company is expanding beyond its traditional strengths to establish a more integrated regenerative medicine and biopharmaceutical support platform.
The CREATIVE LIFE SCIENCE Zhubei Biomedical Factory has been designed in accordance with PIC/S GMP standards and includes dedicated manufacturing areas, quality control laboratories, and testing infrastructure. Internationally aligned equipment systems have also been introduced to support standardized production processes and product quality management.
Since initiating its regenerative medicine transformation strategy in 2021, CREATIVE LIFE SCIENCE has continued to strengthen both its technological capabilities and international collaborations. In recent years, the company has expanded into cell therapy-related fields, while also actively developing partnerships with global organizations across Japan, Singapore, and other international markets.
In 2025, CREATIVE LIFE SCIENCE further strengthened its international regenerative medicine network through collaboration agreements with Kyoto University-originated startup Myoridge in Japan and Singapore-based Esco Aster, supporting the company’s broader global expansion strategy.
Looking ahead, CREATIVE LIFE SCIENCE plans to continue advancing its regenerative medicine manufacturing capabilities, international quality certifications, and global supply chain development. The company is also preparing for future TFDA approvals, Drug Master File (DMF) registrations, and international EXCiPACT GMP certifications to further support customers operating in highly regulated markets.
Chairman Tsai emphasized that the company’s next phase of growth will focus on building long-term international partnerships and supporting the global commercialization of regenerative medicine products.
“We believe the future of regenerative medicine will be built through strong collaboration across science, manufacturing, and quality systems,” Tsai added.
“CREATIVE LIFE SCIENCE is committed to becoming a reliable long-term partner for companies seeking both technical excellence and global regulatory readiness.”
By 2028–2030, CREATIVE LIFE SCIENCE aims to further expand its international market presence and establish a broader global network for regenerative medicine manufacturing and supply chain integration, reinforcing Taiwan’s role within the global biotechnology ecosystem.
(CREATIVE LIFE SCIENCE executives and distinguished guests participate in the opening ceremony of the Zhubei Biomedical Factory, celebrating a new chapter in regenerative medicine and advanced biomanufacturing.)